Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


US Food and Drug Administration

FDA issues guidance on developing new genetic tests for diagnosis and treatment of disease

The US Food and Drug Administration (FDA) has issued two sets of guidance to drive the design, development and validation of new genetic and genomic-based tests using next generation sequencing (NGS).

NGS works by looking at a person’s DNA to detect genomic variations that may determine whether a person has, or is at risk of developing, a genetic disease, and can help inform treatment decisions.

The first set of guidance entitled ‘Use of public human genetic variant databases to support clinical validity of genetic and genomic-based in vitro diagnostics’, describes an approach where test developers can use clinical evidence from FDA-recognised public databases to provide assurance of the accurate clinical evaluation of genomic test results.

The second set of guidance, ‘Considerations for design, development, and analytical validation of next generation sequencing (NGS)-based in vitro diagnostics (IVDs) intended to aid in the diagnosis of suspected germline diseases’, provides recommendations on developing NGS-based tests to diagnose individuals with suspected genetic diseases. It also sets out what the FDA will be looking for in a pre-market submission to assess the analytical validity of a test.

“As disease detection technologies rapidly evolve, so too must the FDA’s approach to reviewing these new innovations,” said Scott Gottlieb, FDA Commissioner.

“The new policies issued [on 13 April 2018] provide a modern and flexible framework to generate data needed to support the FDA’s review of NGS-based tests, and give developers new tools to support the efficient development and validation of these technologies.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20204689

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • US Food and Drug Administration entrance

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.